Cerebral enhancement in MOG antibody-associated disease

Paul Elsbernd,Laura Cacciaguerra,Karl N Krecke,John J Chen,David Gritsch,A Sebastian Lopez-Chiriboga,Elia Sechi,Vyanka Redenbaugh,Padraig P Morris,Jonathan L Carter,Dean M Wingerchuk,Jan-Mendelt Tillema,Cristina Valencia-Sanchez,Smathorn Thakolwiboon,Sean J Pittock,Eoin P Flanagan
DOI: https://doi.org/10.1136/jnnp-2023-331137
2023-05-23
Abstract:Introduction Limited data exist on brain MRI enhancement in myelin-oligodendrocyte-glycoprotein (MOG) antibody-associated disease (MOGAD) and differences from aquaporin-4-IgG-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD), and multiple sclerosis (MS). Methods In this retrospective observational study, we identified 122 Mayo Clinic MOGAD patients (1 January 1996–1 July 2020) with cerebral attacks. We explored enhancement patterns using a discovery set (n=41). We assessed enhancement frequency and Expanded Disability Status Scale scores at nadir and follow-up in the remainder (n=81). Two raters assessed T1-weighted-postgadolinium MRIs (1.5T/3T) for enhancement patterns in MOGAD, AQP4+NMOSD (n=14) and MS (n=26). Inter-rater agreement was assessed. Leptomeningeal enhancement clinical correlates were analysed. Results Enhancement occurred in 59/81 (73%) MOGAD cerebral attacks but did not influence outcome. Enhancement was often patchy/heterogeneous in MOGAD (33/59 (56%)), AQP4+NMOSD (9/14 (64%); p=0.57) and MS (16/26 (62%); p=0.63). Leptomeningeal enhancement favoured MOGAD (27/59 (46%)) over AQP4+NMOSD (1/14 (7%); p=0.01) and MS (1/26 (4%); p 3 months) was rare (0%–8%) across all groups. Inter-rater agreement for enhancement patterns was moderate. Conclusions Enhancement is common with MOGAD cerebral attacks and often has a non-specific patchy appearance and rarely persists beyond 3 months. Leptomeningeal enhancement favours MOGAD over AQP4+NMOSD and MS.
surgery,psychiatry,clinical neurology
What problem does this paper attempt to address?